American Conference
Institute (ACI) will be holding its 17th annual Drug and Medical Device
Litigation conference on December 3-5, 2012 in New York, NY. The conference will allow attendees to:
• Assert a
successful preemption defense and manage parallel plaintiff claims in a post-Mensing world;
• Impeach witness
credibility and dilute the plaintiff witness' opinion via a Daubert challenge;
• Adhere to strict
litigation budgets set by counsel in this tight economy;
• Utilize the
learned intermediary doctrine as a key defense when members of the sales team
are forced to testify;
• Manage cumbersome
global discovery demands;
• Establish in
cross-examination that product risks were contained on the label and were not
withheld by the company; and
• Mitigate the
risks of shareholder derivative litigation stemming from recall and adverse
event activity.
In particular,
ACI's faculty will offer presentations on the following topics:
• Asserting a
successful preemption defense and managing parallel plaintiff claims in a post-Mensing world;
• Industry keynote
address;
• Preparing your
sales and compliance teams for their day in court;
• Managing
litigation in a tough economy: Containing litigation costs with a restricted
budget;
• Operating in an
aggressive enforcement climate: Proactive litigation strategies for responding
to government investigations and thwarting individual accountability (breakout
session);
• Class action
litigation trends & innovations: Emerging theories of liability,
certification, and new developments (breakout session);
• Dissecting
evolving claims against generic drugs and the naming of brand manufacturers as
co-defendants (breakout session);
• Controlling the
witness message: Using medical records and testimony to demonstrate that the
company did what was best for patient safety (breakout session);
• Exploring device
manufacturers' duty to train physicians on the effective use of a particular
device (breakout session);
• Preparing and
defending Daubert challenges to
causation expert testimony: Utilizing the theory in practice (breakout
session);
• Implementing best
practices for bellwether trial selection in mass tort litigation;
• View from the
Bench: Current judicial views on pharmaceutical and medical device litigation;
• Defending new and
emerging claims rising out of shareholder derivative lawsuits against life
sciences companies;
• Analyzing
products liability trends outside the U.S. -- Coordinating litigation efforts
across international jurisdictions; and
• Taking the social
media plunge: Engaging customers online while minimizing the inherent
litigation risks of viral communication.
In addition, a pre-conference jury selection session on "Novel Strategies, Tactics and Ethical Considerations for Selecting the Right Jury" will be offered from 9:00 am to 12:30 pm on December 3, 2012, and a pre-conference group meet-up will be held from 3:00 to 5:00 pm on December 3, 2012. A post-conference business development master class entitled "In-House Counsel Perspectives on Selecting and Evaluating Outside Counsel" will be offered from 3:30 pm to 5:30 pm on December 5, 2012.
The agenda for the Drug and Medical Device Litigation conference can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration
fee for the conference is $2,695 (conference and group meet-up), $3,295
(conference, group meet-up, and workshop or master class), or $3,695
(conference, group meet-up, workshop, and master class). Those registering by September 27, 2012 will
receive a $500 discount, and those registering by November 2, 2012 will receive
a $200 discount. Patent Docs readers who reference the discount code "PD
200" will receive $200 off the current price tier when registering. Those interested in registering for the
conference can do so here, by calling
1-888-224-2480, by faxing a registration form to 1-877-927-1563, or by
e-mailing [email protected].
Patent Docs is a media partner of the Drug and Medical Device Litigation conference.
Comments